Pneumagen
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Pneumagen has raised €9.1M across 2 funding rounds from 2 investors, most recently a round in Jan 2022. Based in Saint Andrews, UK; founded 2016; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€9.1M
€9,069,616
Funding rounds
2
Investors
2
distinct backers
Active since
2020-05
latest 2022-01
Funding by year
EUR raised per yearPneumagen — funding by year — interactive chart.
Data table
| Pneumagen — funding by year | |
|---|---|
| 2020 | €4.5M |
| 2022 | €4.6M |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ 10y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-01-19 | Other | €4.6M | Scottish Enterprise,Thairm Bio | View deal → |
| 2020-05-27 | Early VC | €4.5M | Thairm Bio | View deal → |
Investors
2Related news
- Pneumagen Raises £3.8M in Fundingfinsmes.com · 2022-01
- finsmes.com
Similar companies
same sector or countryGlobal coverage: FundingData